HUTCHMED (CHINA) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290 GBX | -4.61% |
|
+7.41% | +2.47% |
| 04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| 04-26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
| Sales 2024 * | 681M 54.55B | Sales 2025 * | 836M 66.91B | Capitalization | 3.08B 247B |
|---|---|---|---|---|---|
| Net income 2024 * | -109M -8.73B | Net income 2025 * | -6M -480M | EV / Sales 2024 * | 4.23 x |
| Net cash position 2024 * | 199M 15.89B | Net cash position 2025 * | 306M 24.47B | EV / Sales 2025 * | 3.32 x |
| P/E ratio 2024 * |
-26.7
x | P/E ratio 2025 * |
561
x | Employees | 1,988 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on HUTCHMED (China) Limited
More recommendations
More press releases
| 1 day | -4.61% | ||
| 1 week | +7.41% | ||
| Current month | +8.41% | ||
| 1 month | +9.85% | ||
| 3 months | +41.81% | ||
| 6 months | +3.20% | ||
| Current year | +2.47% |
1 week
262.00
312.00
1 month
258.00312.00
Current year
190.40312.00
1 year
173.60338.00
3 years
130.00656.00
5 years
130.00656.00
10 years
74.00656.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 31/12/04 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 30/06/08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 31/12/99 |
Graeme Jack
BRD | Director/Board Member | 73 | 28/02/17 |
Dan Eldar
BRD | Director/Board Member | 70 | 31/07/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 290 | -4.61% | 117,319 |
| 25/04/24 | 304 | +2.70% | 204,831 |
| 24/04/24 | 296 | +2.07% | 53,971 |
| 23/04/24 | 290 | +5.07% | 302,868 |
| 22/04/24 | 276 | +2.22% | 253,307 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Sector
Pharmaceuticals
Calendar
10/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.612
USD
Average target price
5.412
USD
Spread / Average Target
+49.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.47% | 3.08B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HCM Stock
